- Home
- ALNY vs WEC Comparison
ALNY vs WEC Comparison
Compare ALNY & WEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- WEC
- Stock Information
- Founded
- ALNY 2002
- WEC 1896
- Country
- ALNY United States
- WEC United States
- Employees
- ALNY N/A
- WEC N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- WEC Power Generation
- Sector
- ALNY Health Care
- WEC Utilities
- Exchange
- ALNY Nasdaq
- WEC Nasdaq
- Market Cap
- ALNY 42.9B
- WEC 33.8B
- IPO Year
- ALNY 2004
- WEC N/A
- Fundamental
- Price
- ALNY $343.69
- WEC $109.38
- Analyst Decision
- ALNY Strong Buy
- WEC Hold
- Analyst Count
- ALNY 25
- WEC 10
- Target Price
- ALNY $347.75
- WEC $104.60
- AVG Volume (30 Days)
- ALNY 869.5K
- WEC 1.7M
- Earning Date
- ALNY 07-31-2025
- WEC 07-30-2025
- Dividend Yield
- ALNY N/A
- WEC 3.29%
- EPS Growth
- ALNY N/A
- WEC 12.23
- EPS
- ALNY N/A
- WEC 5.14
- Revenue
- ALNY $2,348,099,000.00
- WEC $9,069,200,000.00
- Revenue This Year
- ALNY $32.73
- WEC $9.91
- Revenue Next Year
- ALNY $31.50
- WEC $5.09
- P/E Ratio
- ALNY N/A
- WEC $21.13
- Revenue Growth
- ALNY 17.21
- WEC 4.42
- 52 Week Low
- ALNY $205.87
- WEC $83.13
- 52 Week High
- ALNY $333.70
- WEC $111.00
- Technical
- Relative Strength Index (RSI)
- ALNY 64.89
- WEC 58.19
- Support Level
- ALNY $323.74
- WEC $104.16
- Resistance Level
- ALNY $332.19
- WEC $110.35
- Average True Range (ATR)
- ALNY 7.50
- WEC 1.60
- MACD
- ALNY 0.31
- WEC 0.28
- Stochastic Oscillator
- ALNY 94.08
- WEC 74.70
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy and 2% LNG distribution and generation.